{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT02815488: Phase 1/Phase 2 Interventional Terminated Chronic Obstructive Pulmonary Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:Sunvozertinib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01125644: Phase 3 Interventional Unknown status Cryptococcosis or Aspergillosis Infections
(2010)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
SPK-843 is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows in vitro inhibitory activity comparable to or better than that of Amphotericin B against Candida spp., Cryptococcus neoformans, and Aspergillus spp. SPK-843 exhibits dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) and liposomal amphotericin B.
Status:
Investigational
Source:
NCT03092934: Phase 1/Phase 2 Interventional Completed Neoplasms
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01211249: Phase 2 Interventional Completed Rheumatoid Arthritis
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04270591: Phase 1/Phase 2 Interventional Recruiting C-Met Exon 14 Mutation
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04541082: Phase 1 Interventional Recruiting Central Nervous System Neoplasms
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:ruclosporin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ruclosporin is a calcineurin inhibitor that was developed as an immunosuppressant. Information about the further development of this compound is not available.
Status:
Investigational
Source:
NCT03903549: Phase 1 Interventional Completed Parkinson Disease
(2022)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
